A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

NCT05564039 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication tirzepatide in adults with type 2 diabetes who are switching from dulaglutide to see how it affects their blood sugar levels.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 282 people

Who can join Ages 18+ · all sexes

Timeline Started 2022-11 · est. completion 2024-08

Where 38 sites · Belgium, Germany, Mexico, Romania, United States

What this study is testing ClinicalTrials.gov NCT05564039 ↗

Description as written by the study sponsor.

The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Dulaglutide also known as LY2189265 Drug

Administered SC

Main thing measured	Change From Baseline in HbA1c
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes
GLP-1 drugs	tirzepatide, dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05564039 ↗